Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure
Aim: To assesses the cost-effectiveness of sotagliflozin for the treatment of patients hospitalized with heart failure and comorbid diabetes. Materials & methods: A de novo cost-effectiveness model with a Markov structure was created for patients hospitalized for heart failure with comorbid diab...
Saved in:
Main Authors: | Jaehong Kim (Author), Shanshan Wang (Author), Slaven Sikirica (Author), Jason Shafrin (Author) |
---|---|
Format: | Book |
Published: |
Becaris Publishing Limited,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis
by: Weichen Zhang, et al.
Published: (2024) -
The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings
by: Fitch K, et al.
Published: (2018) -
Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis
by: Jiyifan Li, et al.
Published: (2023) -
The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
by: Rendell MS
Published: (2019) -
Association of persistent and transient worsening renal function with mortality risk, readmissions risk, length of stay, and costs in patients hospitalized with acute heart failure
by: Palmer JB, et al.
Published: (2015)